Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Treatment discontinuation should not be viewed merely as an adverse event, but as a clinically meaningful signal reflecting both patient vulnerability and potential loss of therapeutic benefit. These observations suggest that the effectiveness of neurohormonal therapies may depend as much on their sustained use as on their intrinsic pharmacologic efficacy.”
“There might be a beneficial effect of spironolactone in these patients if they are able to be on drug treatment.”
“Since it was underpowered, with a 65% likelihood of a type II error, we cannot talk about efficacy for the primary or any of the secondary endpoints.”
In older, multi-morbid patients with HFpEF and HFmrEF, the effectiveness of neurohormonal therapies depends heavily on sustained use and long-term tolerability, not just intrinsic pharmacologic efficacy.
Taken together, the findings from SPIRIT-HF challenge a simplistic interpretation of neutral trial results from an under-powered study, and instead appear to highlight the critical role of treatment durability in determining clinical outcomes in heart failure with preserved ejection fraction and heart failure with mildly reduced ejection fraction, where patients are older, multi-morbid, and physiologically vulnerable, the balance between efficacy and tolerability is particularly fragile. Importantly, treatment discontinuation should not be viewed merely as an adverse event, but as a clinically meaningful signal reflecting both patient vulnerability and potential loss of therapeutic benefit. These observations suggest that the effectiveness of neurohormonal therapies may depend as much on their sustained use as on their intrinsic pharmacologic efficacy. Accordingly, future therapeutic strategies should prioritize not only the initiation of disease-modifying treatments but also their long-term tolerability, adherence, and continuity.
No takes yet. Share an insight, caveat, or question.
Copeland et al. (2026) conducted an editorial in Heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) (n=730). Spironolactone vs. Placebo was evaluated on Recurrent heart failure hospitalizations over 24 months and cardiovascular mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: